BACKGROUND: The high cardiotoxicity morbidity and mortality rates associated with the antineoplastic therapy for breast cancer could be reduced with the early use of cardioprotective drugs. However, the low sensitivity of left ventricular ejection fraction limits its use in that preventive strategy. New parameters, such as global longitudinal strain, are being used in the early detection of contractile function changes. OBJECTIVES: To assess the incidence of cardiotoxicity in patients treated for breast cancer, the independent factors associated with that event, and the ability of strain to identify it early. METHODS: Prospective observational study of consecutive outpatients diagnosed with breast cancer, with no previous antineoplastic treatment and no ventricular dysfunction, who underwent anthracycline and/or trastuzumab therapy. The patients were quarterly evaluated on a 6- to 12-month follow-up by an observer blind to therapy. Cox regression was used to evaluate the association of cardiotoxicity with clinical, therapeutic and echocardiographic variables. A ROC curve was built to identify the strain cutoff point on the third month that could predict the ejection fraction reduction on the sixth month. For all tests, the statistical significance level adopted was p ≤ 0.05. RESULTS: Of 49 women (mean age, 49.7 ± 12.2 years), cardiotoxicity was identified in 5 (10%) on the third (n = 2) and sixth (n = 3) months of follow-up. Strain was independently associated with the event (p = 0.004; HR = 2.77; 95%CI: 1.39-5.54), with a cutoff point for absolute value of -16.6 (AUC = 0.95; 95%CI: 0.87-1.0) or a cutoff point for percentage reduction of 14% (AUC = 0.97; 95%CI: 0.9-1.0). CONCLUSION: The 14% reduction in strain (absolute value of -16.6) allowed the early identification of patients who could develop anthracycline and/or trastuzumab-induced cardiotoxicity.
BACKGROUND: The high cardiotoxicity morbidity and mortality rates associated with the antineoplastic therapy for breast cancer could be reduced with the early use of cardioprotective drugs. However, the low sensitivity of left ventricular ejection fraction limits its use in that preventive strategy. New parameters, such as global longitudinal strain, are being used in the early detection of contractile function changes. OBJECTIVES: To assess the incidence of cardiotoxicity in patients treated for breast cancer, the independent factors associated with that event, and the ability of strain to identify it early. METHODS: Prospective observational study of consecutive outpatients diagnosed with breast cancer, with no previous antineoplastic treatment and no ventricular dysfunction, who underwent anthracycline and/or trastuzumab therapy. The patients were quarterly evaluated on a 6- to 12-month follow-up by an observer blind to therapy. Cox regression was used to evaluate the association of cardiotoxicity with clinical, therapeutic and echocardiographic variables. A ROC curve was built to identify the strain cutoff point on the third month that could predict the ejection fraction reduction on the sixth month. For all tests, the statistical significance level adopted was p ≤ 0.05. RESULTS: Of 49 women (mean age, 49.7 ± 12.2 years), cardiotoxicity was identified in 5 (10%) on the third (n = 2) and sixth (n = 3) months of follow-up. Strain was independently associated with the event (p = 0.004; HR = 2.77; 95%CI: 1.39-5.54), with a cutoff point for absolute value of -16.6 (AUC = 0.95; 95%CI: 0.87-1.0) or a cutoff point for percentage reduction of 14% (AUC = 0.97; 95%CI: 0.9-1.0). CONCLUSION: The 14% reduction in strain (absolute value of -16.6) allowed the early identification of patients who could develop anthracycline and/or trastuzumab-induced cardiotoxicity.
Authors: Heloisa Sawaya; Igal A Sebag; Juan Carlos Plana; James L Januzzi; Bonnie Ky; Victor Cohen; Sucheta Gosavi; Joseph R Carver; Susan E Wiegers; Randolph P Martin; Michael H Picard; Robert E Gerszten; Elkan F Halpern; Jonathan Passeri; Irene Kuter; Marielle Scherrer-Crosbie Journal: Am J Cardiol Date: 2011-03-02 Impact factor: 2.778
Authors: Timothy C Tan; Souhila Bouras; Heloisa Sawaya; Igal A Sebag; Victor Cohen; Michael H Picard; Jonathan Passeri; Irene Kuter; Marielle Scherrer-Crosbie Journal: J Am Soc Echocardiogr Date: 2015-03-13 Impact factor: 5.251
Authors: André Luiz Cerqueira de Almeida; Viviane Almeida Silva; Alberto Teófilo de Souza Filho; Vinicius Guedes Rios; João Ricardo Pinto Lopes; Samuel Oliveira de Afonseca; Daniel de Castro Araújo Cunha; Murilo Oliveira da Cunha Mendes; Danilo Leal Miranda; Edval Gomes dos Santos Júnior Journal: Arq Bras Cardiol Date: 2015-01-27 Impact factor: 2.000
Authors: Jose Luis Zamorano; Patrizio Lancellotti; Daniel Rodriguez Muñoz; Victor Aboyans; Riccardo Asteggiano; Maurizio Galderisi; Gilbert Habib; Daniel J Lenihan; Gregory Y H Lip; Alexander R Lyon; Teresa Lopez Fernandez; Dania Mohty; Massimo F Piepoli; Juan Tamargo; Adam Torbicki; Thomas M Suter Journal: Eur Heart J Date: 2016-08-26 Impact factor: 29.983
Authors: Reham Selmy Abo El Magd Rasheed; Hatem Mohammed Fathy El Sokkary; Mahmoud Zaki El Amrosy; Mohammed El Sayd El Setiha; Mai Mohammed Abd El Moneim Salama Journal: J Saudi Heart Assoc Date: 2022-07-01
Authors: Elissa A S Polomski; Julius C Heemelaar; Augustinus D G Krol; Marloes Louwerens; Saskia L M A Beeres; Eduard R Holman; J Wouter Jukema; Martin J Schalij; M Louisa Antoni Journal: Cancers (Basel) Date: 2022-05-08 Impact factor: 6.575
Authors: K A Jones; A D Small; S Ray; D J Hamilton; W Martin; J Robinson; N E R Goodfield; C A Paterson Journal: J Nucl Cardiol Date: 2020-08-03 Impact factor: 5.952
Authors: Jack Rubinstein; Jessica G Woo; Anastacia M Garcia; Tarek Alsaied; Jia Li; Per Kristian Lunde; Ryan A Moore; Martin Laasmaa; Amanda Sammons; Wayne A Mays; Shelley D Miyamoto; William E Louch; Gruschen R Veldtman Journal: Pediatr Cardiol Date: 2020-08-07 Impact factor: 1.655